Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 20/20 | 0.47 |
| ▸ | GPR183 | P32249 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386524 | 0.85 | GPR119 (0.64) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL387959 | 0.85 | GPR119 (0.64) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL387520 | 0.85 | GPR119 (0.64) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL1802668 | 0.80 | ACACB (0.32) | — | |
| SCHEMBL1846590 | 0.80 | ACACB (0.32) | — | |
| SCHEMBL29850755 | 0.79 | GPR119 (0.41) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL19434812 | 0.79 | GPR119 (0.41) | GPR119GPR183CYP3A4CYP2C19 | |
| SCHEMBL1805040 | 0.79 | GPR119 (0.39) | GPR119 | |
| SCHEMBL1843716 | 0.79 | GPR119 (0.39) | GPR119 | |
| SCHEMBL1846048 | 0.79 | GPR119 (0.36) | GPR119CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140249156-A1 | Treatment Of Blood Lipid Abnormalities And Other Conditions | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | claimed |
| JP-2011529897-A | — | — | 2011-12-15 | — | — | JP | claimed |
| US-20110124652-A1 | Chemical Compounds and Uses | SMITHKLINE BEECHAM CORPORATION | 2011-05-26 | — | — | US | claimed |
| WO-2010014593-A1 | CHEMICAL COMPOUNDS AND USES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | WO | claimed |
| EP-2776039-A2 | TREATMENT OF BLOOD LIPID ABNORMALITIES AND OTHER CONDITIONS | GlaxoSmithKline LLC (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20140249156-A1 | Treatment Of Blood Lipid Abnormalities And Other Conditions | GLAXOSMITHKLINE LLC (US) | 2014-09-04 | — | — | US | disclosed |
| WO-2013070463-A2 | TREATMENT OF BLOOD LIPID ABNORMALITIES AND OTHER CONDITIONS | GLAXOSMITHKLINE LLC (US) | 2013-05-16 | — | — | WO | disclosed |
| US-20110124652-A1 | Chemical Compounds and Uses | SMITHKLINE BEECHAM CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-20110124652-A1 | Chemical Compounds and Uses | SMITHKLINE BEECHAM CORPORATION | 2011-05-26 | — | — | US | disclosed |
| US-20110124652-A1 | Chemical Compounds and Uses | SMITHKLINE BEECHAM CORPORATION | 2011-05-26 | — | — | US | disclosed |
| EP-2320910-A1 | CHEMICAL COMPOUNDS AND USES | GlaxoSmithKline LLC (US) | 2011-05-18 | — | — | EP | disclosed |
| WO-2010014593-A1 | CHEMICAL COMPOUNDS AND USES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010014593-A1 | CHEMICAL COMPOUNDS AND USES | SMITHKLINE BEECHAM CORPORATION (US) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124652-A1 | Chemical Compounds and Uses | GOT2, GPR119, SLC5A2 | GPR119 2/4885GPR183 1837/4885CYP3A4 552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.